VANCOUVER, British Columbia, Jan. 5, 2011 (GLOBE NEWSWIRE) -- Global Health Ventures Inc. (OTCBB:GHLV) - a specialty pharmaceutical company with expertise in drug delivery and formulation - announced today that it has retained Premier Media Service Inc. as its investor relations firm. Arizona-based Premier Media Service Inc. is a full service investor and media relations consulting firm, providing both private and publicly traded companies customized programs to generate awareness among members of the financial community. Premier Media specializes in accelerating growth in the value of small to mid-size companies.
Hassan Salari, Ph.D., Chairman & CEO, said, "We are pleased to be associated with Premier Media Service. Global Health Ventures has made great progress in developing its a patented proprietary platform technology for drug delivery via the sublingual (under the tongue) route technology and I believe Premier will play an important role in helping us get our message out to the investment and financial community as well as our current and potential future investors."
Kelly Black, President, PMSI, stated, "We are proud to work with Global Health Ventures in incorporating the advertising services of various media outlets exposing our portfolio companies to the public markets. We are impressed with the company's unique drug delivery system, high quality standards of management and unique market opportunities the company is able to achieve through their disciplined growth strategies."
About Global Health Ventures Inc.
Global Health Ventures Inc. (OTCBB:GHLV) is a specialty pharmaceutical company with expertise in drug delivery and formulation. The Company has a proprietary platform technology for drug delivery via the sublingual (under the tongue) route. This unique method delivers drugs to the bloodstream quickly with minimal drug breakdown in the liver or gastrointestinal system, a process that can greatly reduce side effects associated with the drugs. The Company's lead therapeutic product is a male sexual enhancement drug that is delivered via sublingual route and is called X-Excite. In experimental studies, X-Excite has been shown to reach the blood stream rapidly, producing maximal effect and having less of the unwanted side effects associated with oral delivery route. X-Excite is presently in clinical development in Europe. The Company's second drug "Relax-B" is also under development in Canada for anxiety. And, the third drug will be an anti-migraine drug. The Company plans to use the same technology to deliver a vast number of other FDA approved and non-approved drugs that require faster delivery, or reduced hepatic and gastrointestinal side effects. These include stress relief, sleeping disorders, pain killers, anti-allergy medications, energy boosters and addiction replacement therapies. For more information visit their corporate fact sheet http://premierstocks.tv/images/company_links/GHLVlogo.pdf
About Premier Media Service Inc.: (PMSI) is a full-service public relations consulting firm dedicated to providing broadcast news and financial marketing services. PMSI offers multi-faceted public and investor relations campaigns designed to maximize institutional and private investor awareness of companies traded on all major exchanges. PMSI produces a bi-monthly broadcast news show, as well as produces live CEO Interviews, conference filming, television commercials and other broadcast services through its wholly-owned subsidiary, www.premierstocks.tv/">PremierStocks.TV (PSTV) (www.premierstocks.tv/">www.PremierStocks.tv or www.HotChicksStockPicks.com/">www.HotChicksStockPicks.com or www.GreenStocksRock.com/">www.GreenStocksRock.com).
Notice Regarding Forward-Looking Statements - This press release includes forward-looking statements that involve a number of risks and uncertainties, including the success of the products in commercializing and developing. Further, the risks involve the ability of the Company to raise capital to fund its operations and the capital requirements for the development and marketing of its products. Investors are encouraged to review the risk factors listed or described from time to time in the Company's filings (10K) with the Securities and Exchange Commission.